Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Journal Article

Local Library Link: Find It @ Loyola

Authors: Nagda, S. N.; Mohideen, N.; Lo, S. S.; Khan, U.; Dillehay, G.; Wagner, R.; Campbell, S.; Flanigan, R.C.
Article Title: Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Abstract: PURPOSE: To evaluate the long-term failure patterns in patients who underwent an (111)In-capromab pendetide (ProstaScint) scan as part of their pretreatment assessment for a rising prostate-specific antigen (PSA) level after prostatectomy and subsequently received local radiotherapy (RT) to the prostate bed. METHODS: Fifty-eight patients were referred for evaluation of a rising PSA level after radical prostatectomy. All patients had negative findings for metastatic disease after abdominal/pelvis imaging with CT and isotope bone scans. All patients underwent a capromab pendetide scan, and the sites of uptake were noted. All patients were treated with local prostate bed RT (median dose 66.6 Gy). RESULTS: Of the 58 patients, 20 had biochemical failure (post-RT PSA level gt;0.2 ng/mL or a rise to greater than the nadir PSA), including 6 patients with positive uptake outside the bed (positive elsewhere). The 4-year biochemical relapse-free survival (bRFS) rates for patients with negative (53%), positive in the prostate bed alone (45%), or positive elsewhere (74%) scan findings did not differ significantly (p = 0.51). The positive predictive value of the capromab pendetide scan in detecting disease outside the bed was 27%. The capromab pendetide scan status had no effect on bRFS. Those with a pre-RT PSA level of lt;1 ng/mL had improved bRFS (p = 0.003). CONCLUSION: The capromab pendetide scan has a low positive predictive value in patients with positive elsewhere uptake and the 4-year bRFS was similar to that for those who did not exhibit positive elsewhere uptake. Therefore, patients with a postprostatectomy rising PSA level should considered for local RT on the basis of clinicopathologic factors.
Journal Title: International journal of radiation oncology, biology, physics
Volume: 67
Issue: 3
ISSN: 1879-355X; 0360-3016
Publisher: Elsevier Inc  
Journal Place: United States
Date Published: 2007
Start Page: 834
End Page: 840
Language: English
Notes: ID: 1336; Record Owner: NLM; Status: MEDLINE; Publishing Model: Journal available in: Print Citation processed from: Print; NLM Journal Code: g97, 7603616; CAS Registry/EC Number/Name of Substance: 0 (Antibodies, Monoclonal). 0 (Indicators and Reagents). 0 (Indium Radioisotopes). 145464-28-4 (Capromab Pendetide). EC 3-4-21-77 (Prostate-Specific Antigen).; Entry Date: 20070409